Illumina raises 2026 revenue outlook and reports strong Q3 performance driven by NovaSeq X demand
Illumina announced that its third‑quarter operating cash flow was $419 million and free cash flow $378 million. The company lifted its full‑year 2026 revenue guidance to a range of $4.64 billion‑$4.66 billion and expects diluted EPS of $5.40‑$5.45. Q3 revenue came in at $1.17 billion, up 4.7% year‑over‑year on a rest‑of‑world organic basis, while more than 80 NovaSeq X instruments were installed during the quarter, taking cumulative placements over the last four quarters to roughly 360. Management highlighted continued clinical sequencing demand, progress on the BioInsight data platform and a return to growth in China.
Why it matters
The raised revenue and EPS guidance suggests higher earnings potential for the remainder of 2026, which could support the stock price and affect analysts' target revisions. The strong NovaSeq X uptake signals accelerating instrument adoption, likely boosting consumables sales and margin expansion in upcoming quarters.
Key facts
- 1Operating cash flow for Q3 was $419 million. finance.yahoo.com
- 2Free cash flow for Q3 was $378 million. finance.yahoo.com
- 3Full‑year 2026 revenue guidance was increased to $4.64 billion‑$4.66 billion, a $30 million midpoint lift. finance.yahoo.com
- 4Full‑year diluted EPS guidance was raised to $5.40‑$5.45. finance.yahoo.com
- 5Q3 2026 revenue was $1.17 billion, a 4.7% increase year‑over‑year on a rest‑of‑world organic basis. finance.biggo.com
- 6Diluted EPS for Q3 was $1.44, up 7% from the prior quarter. finance.biggo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.